Patents Represented by Attorney John C. Demeter
  • Patent number: 7067510
    Abstract: The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1–C4 alkyl), —OCOC6H5, —OCO(C1–C6 alkyl), or —OSO2(C2–C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1–C4 alkyl), —OCOC6H5, —OCO(C1–C6 alkyl), —OSO2(C2–C6 alkyl) or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is —S— or —HC?CH—; G is —O—, —S—, —SO—, SO2, or —N(R5)—, wherein R5 is —H or C1–C4 alkyl; and Y is —O—, —S—, —NH—, —NMe-, or —CH2—; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: June 27, 2006
    Assignee: Eli Lilly and Company
    Inventor: Owen Brendan Wallace
  • Patent number: 7056931
    Abstract: The current invention provides novel 2-substituted 1,2,3,4-tetrahydroquinolin-6-ols and derivatives thereof of the formula (I) (A); pharmaceutical compositions thereof, optionally in combination with estrogen or progestin; methods for inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: June 6, 2006
    Assignee: Eli Lilly and Company
    Inventor: Owen Brendan Wallace
  • Patent number: 7009060
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: December 24, 2002
    Date of Patent: March 7, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cynthia Darshini Jesudason, Don Richard Finley
  • Patent number: 6983843
    Abstract: The invention is particularly, although not exclusively, concerned with a protective container (1; 1?) for fragile articles (100), such as bottles, vials or ampoules of fluid medicament. In one aspect, the protective container is provided with impact energy-absorbing structural features for protecting the fragile article in the event of it being dropped, for instance impact energy-absorbing collars (45, 47; 45?, 47?) at, or adjacent to, the forward and rear end surfaces, respectively. In other aspects of the invention, the protective container (1; 1?) has a hanging member (17; 17?) and/or a corrugated wall structure (37, 39, 41, 43; 37?, 39?41?43?) and/or a latchable flap (55; 55?) for a dispensing aperture (57; 57?) in the container. In yet further aspects, there is provided a protective container having a re-formable label (101; 101?) and/or an internal skirt (73; 73?) for locating and retaining a feature on an article to be housed therein.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: January 10, 2006
    Assignee: Eli Lilly and Company
    Inventors: Peter Van Geert, Mischa Marteleur, Johan Berte
  • Patent number: 6955818
    Abstract: A non-irritant topically acceptable carrier selected from the group consisting of: a) i) at least one of tripropylene glycol methyl ether and dipropylene glycol methyl ether, and ii) at least one of alcohol, wool grease and propylene glycol, wherein (i) is present in an amount of at least about 60% wt of the carrier; b) i) at least one of octyl palmitate, octyl stearate and glyceryl tri caprylate/caprate, and ii) at least one of dioctyl succinate, isopropyl myristate, cetearyl octanoate, propylene glycol 2 myristyl ether propionate, isopropyl palmitate, isopropyl laurate, isocetyl stearate, oleic acid and methyl oleate, and optionally including iii) at least one of alcohol, wool grease and propylene glycol, wherein (ii) is present in an amount of up to about 40% wt of the carrier; and c) i) at least one of octyl palmitate, octyl stearate and glyceryl tri caprylate/caprate, and ii) at least one of alcohol, wool grease and propylene glycol, wherein (i) is present in an amount of at least about 60% wt of the car
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: October 18, 2005
    Assignee: Eli Lilly and Company
    Inventors: Kristina Clare Hacket, Lionel Barry Low, James Terence Rothwell
  • Patent number: 6933318
    Abstract: This invention provides topical ectoparasiticidal fomulations comprising an ectoparasiticide, preferably a pyrethroid or a spinosyn, a spreading agent at is a (C3-C6) branched alkyl (C10-C20) alkanoate, preferably isopropyl myristate, and optionally a miscibilizing agent compatible with organic solvent systems, and methods of controlling an ectoparasite infestation on certain animals comprising topically applying such formulations to the animal.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: August 23, 2005
    Assignee: Eli Lilly and Company
    Inventors: James Web Kassebaum, Paul Thomas Pugh, William Webster Thompson
  • Patent number: 6927210
    Abstract: The invention provides a stable ectoparasiticidal aqueous suspension formulation of a spinosyn, comprising the spinosyn, or a physiologically acceptable derivative or salt thereof, milled to an average particle size of 1 to 15 microns, a surfactant in an amount effective to facilitate wetting the milled particles; a dispersant in an amount that forms a spinosyn;dispersant weight ration of from 3:1 to 1:5; and water. It also provides a method of controlling an ectoparasite infestation on a small ruminant or companion animal comprising administering an effective amount of such an aqueous suspension formulation.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: August 9, 2005
    Assignee: Eli Lilly and Company
    Inventors: William Webster Thompson, Joseph Raymond Winkle
  • Patent number: 6841563
    Abstract: Disclosed is a compound represented by structural formula (I): R1 is a substituted or unsubstituted aryl group. R2 and R3 are independently —H, a C1-C4 straight chained or branched alkyl group. R4 and R5 are independently —H, a C1-C4 straight chained or branched alkyl group or, taken together with the nitrogen atom to which each is bonded, a non-aromatic heterocyclic ring. Ring A and Ring B are independently further substituted with zero, one or two substituents. Physiologically acceptable salts of structural formula shown above are also included. Also disclosed is a method promoting growth, efficiency of feed utilization and/or production of lean body mass in a livestock animal. The method comprises administering to the animal an effective amount of one or more compounds represented by the structural formula as shown or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: January 11, 2005
    Assignee: Eli Lilly and Company
    Inventors: Randall Bruce Hopkins, Deana Lori Hancock, Michael Eugene Quimby
  • Patent number: 6664237
    Abstract: The invention provides single-dose oral formulations for controlling an ectoparasite infestation on a companion animal for a prolonged time, said formulations comprising a spinosyn component, or a physiologically acceptable derivative or salt thereof, and a carrier in oral dosage form. It also provides methods for controlling such infestations comprising orally administering a single dose of these formulations to the animal.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: December 16, 2003
    Assignee: Eli Lilly and Company
    Inventor: Daniel Earl Snyder
  • Patent number: 6664271
    Abstract: Novel compounds and methods for preparing same, immunopotentiating compositions, and a method for potentiating the immune system of a host animal. The method comprises administering to the animal an effective amount of an immunopotentiating compound of Formula I or Formula II, or a physiologically acceptable salt.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: December 16, 2003
    Assignee: Eli Lilly and Company
    Inventors: Lawrence Camillo Creemer, Janice Rhea Herring, Edward Deorsey McGruder
  • Patent number: 6534504
    Abstract: Disclosed is compound represented by Structural Formula (I), wherein Ring A, Ring B and Ring C are independently substituted or unsubstituted. R1 and R2 are independently a C1-C4 straight chained or branched alkyl group. Also disclosed is a method of increasing the quantity and improving quality of meat obtained from a livestock animal. The method comprises administering to the animal an effective amount of one or more compounds represented by Structural Formula (I).
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: March 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Deana Lori Hancock, Randall Bruce Hopkins, Michael Eugene Quimby, Andrew Jason Wuethrich
  • Patent number: 6458377
    Abstract: A dry composition of an ionophore antibiotic such as monensin comprising from 10 to 95% (when expressed as the sodium salt) of at least one crystalline ionophore antibiotic, from 0 to 10% antifoam agent(s), from 0.1 to 20% wetting and/or surfactant agent(s), from 0.1 to 10% dispersal agent(s), and from 0.1 to 20% suspension agent(s). The use of the composition is as a suspension in water alone or in conjunction with a milk replacer composition and/or a milk extender composition in water as a calf feed composition.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: October 1, 2002
    Assignee: Eli Lilly and Company
    Inventors: Lionel B. Lowe, Derek G. Moore
  • Patent number: 6369049
    Abstract: The invention provides new fluorinated cephalosporin antibiotics of Formula I wherein Ra, Rb, Rc, Rd and Re, independently, are H, F or a C1-C6 alkyl-(Z)n— group having at least one fluorine substituent; X is O or S; Y is S, O, or —CH2—; Z is O, S, —SO—, or —SO2—; m and n independently are 0 or 1; and R1 is H, C1-C6-alkyl, phenyl or benzyl, each of which may optionally have up to three substituents selected from halo, C1-C4-alkoxy, phenyl, NO2, C1-C6-alkanoyl, benzoyl, or C1-C6-alkanoyloxy; or a physiologically acceptable salt thereof; and methods of preventing or treating or treating infection, particularly mastitis in ruminants, using these antibiotics.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: April 9, 2002
    Assignee: Eli Lilly and Company
    Inventor: Karl Robert Dahnke
  • Patent number: 6365174
    Abstract: A wettable powder composition of crystalline monensin comprising from 90 to 95% (when expressed as the sodium salt) of crystalline monensin from 0.1 to 2% antifoam agent, from 0.1 to 5% wetting agent, from 0.1 to 5% dispersal agent, and from 0.1 to 5% suspension agent. The use of the composition is as a suspension in water alone or in conjunction with a milk replacer composition or a milk extender composition in water as a calf feed composition.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: April 2, 2002
    Assignee: Eli Lilly and Company
    Inventors: Lionel B. Lowe, Derek G. Moore
  • Patent number: 6342482
    Abstract: Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: January 29, 2002
    Assignee: Eli Lilly and Company
    Inventor: Daniel Earl Snyder
  • Patent number: 6329363
    Abstract: The invention provides new fluorinated cephalosporin antibiotics and methods of preventing or treating infection, particularly mastitis in ruminants, using these antibiotics, and veterinary and pharmaceutical formulations comprising these antibiotics.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company
    Inventor: Karl Robert Dahnke
  • Patent number: 6013828
    Abstract: The present application relates to a series of novel sulfonic acid metal cation salts of the formula ##STR1## which are useful intermediates to prepare antifolate 5-substituted pyrrolo[2,3-d]pyrimidines. The present invention also relates to a novel process for preparing the sulfonic acid metal cation salts and to a novel process for preparing aldehydes of the formula ##STR2## from the corresponding sulfonic acid metal cation salts.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: January 11, 2000
    Assignee: Eli Lilly and Company
    Inventors: Douglas Patton Kjell, Brian James Slattery, Charles Jackson Barnett
  • Patent number: 5846974
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: December 8, 1998
    Assignee: Eli Lilly and Company
    Inventors: Mary J. Kallman, Kurt Rasmussen
  • Patent number: 5816260
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Mary J. Kallman, Kurt Rasmussen
  • Patent number: 5732717
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: March 31, 1998
    Assignee: Eli Lilly and Company
    Inventors: August M. Watanabe, Thomas F. Bumol, Mitchell I. Steinberg, Mary J. Kallman, Kurt Rasmussen